TENAX THERAPEUTICS, INC.
TENX · XNASCIK 34956fmd_02DZ5700CW9NDCJQQ8XE4JGMR9Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: May 01, 2010 to Sep 30, 2026, 68 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | 0 | – | – | – | – | – | – | – | 0 | 0 |
| Cost of revenue | 0 | – | – | – | – | – | – | – | – | – |
| Net interest income | – | – | – | – | 0 | 0 | – | – | – | – |
| Gross profit | 0 | – | – | – | – | – | – | – | – | – |
| Research and development | 13 | 4 | 1 | 3 | 5 | 25 | 5 | 3 | 13 | 33 |
| Selling, general and administrative | 6 | 6 | 6 | 5 | 5 | 8 | – | – | – | – |
| Total operating expenses | 53 | 9 | 7 | 9 | 10 | 33 | 11 | 8 | 19 | 56 |
| Operating income | (53) | (9) | (7) | (9) | 10 | (33) | 11 | (8) | (19) | (56) |
| Interest expense | 0 | – | – | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | 1 | 0 | 0 | 0 | 0 | – | (0) | 0 | 0 | (0) |
| Income tax expense | (8) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income | (44) | (9) | (14) | (8) | (10) | (32) | 11 | (8) | (18) | (53) |
| Net income to common shareholders | 44 | – | – | – | – | – | – | – | – | – |